Your Product Copy Is Why Your Peptide Merchant Account Just Got Frozen

A BPC-157 supplier we looked at last quarter had done everything "right" on paper. Research-only disclaimer in the footer. Age gate on entry. A COA page with batch numbers. And a processor account that got terminated 11 weeks after launch, with 10% of six months' revenue held in reserve and a note in the merchant file that reads, in effect: "site content inconsistent with underwriting agreement."

Nobody scraped their COA page. Nobody flagged the age gate. What killed the account was the product description for their retatrutide blend, which read: "Most users report noticeable appetite suppression within the first week at 2mg. Start low — many find 250mcg every other day is plenty to start." That's not research language. That's dosing instructions for human consumption, written by a copywriter optimizing for conversion, sitting three clicks from a checkout page processing Visa and Mastercard transactions. The legal disclaimer said one thing. The sales copy said another. The account got shut down because of the second one, not the first.

The Compliance Layer and the Conversion Layer Are Usually Written by Different People, at Different Times, for Different Goals

Here's the actual failure mode, and it's structural, not careless. Most peptide sites are built in two passes. Pass one: a compliance consultant or the founder writes the legal scaffolding — the research-use disclaimer, the affirmation gate, the terms of sale. Pass one happens once, gets approved by whoever's underwriting the merchant account, and then gets frozen in a footer template.

Pass two happens continuously, forever, by whoever's running growth. A copywriter rewrites the PDP to lift conversion rate. A CRO consultant adds a "customer results" section with before/after language. An affiliate or ad-buyer writes a landing page for a Meta campaign that says "how much should I take" because that's the exact phrase converting on paid traffic. Every one of those edits happens without the person touching it ever reading the underwriting agreement, because the underwriting agreement isn't in their job.

The result is a site that's legally coherent in the places where lawyers looked and legally incoherent everywhere growth people looked — which, on an ecommerce site, is most of the site. The homepage, every PDP, every blog post, every landing page, and every OG tag pulled into a Facebook ad preview. High-risk processors and the card networks behind them don't care which department wrote which page. They see one domain.

Underwriters and Networks Monitor the Live Site, Not the Application You Submitted

This is the part most first-time peptide founders don't know until it costs them: initial underwriting approves you based on a snapshot — the site as it existed the day you applied, plus the MCC/NAICS code you were boarded under (usually something in the 5122/nutritional-supplement or research-chemical bucket that already carries a high-risk multiplier). But approval isn't the end of monitoring. Processors run ongoing transaction monitoring — automated scans plus, for higher-volume accounts, manual reviews — that check live site content against the terms of the merchant agreement on a recurring basis, often triggered by chargeback ratio movement.

Chargebacks are the second half of the mechanism. Visa's threshold for its standard monitoring program sits around 0.9–1% of transactions; cross that and you're in a formal remediation window before outright termination. Peptide sites run higher natural chargeback rates than almost any other DTC category because customers dispute charges when a product doesn't do what a testimonial or a Reddit thread implied it would — and every one of those disputes gets reviewed with the live site pulled up next to it. A rep looking at a dispute for "product didn't work as described" who then finds a PDP with dosing language and a testimonial about weight loss isn't going to rule in the merchant's favor. That single review can trigger a full account audit, and a full account audit on a site with inconsistent compliance language is how you end up with a rolling reserve — typically 10–20% of volume held for 180 days — or an outright termination that gets reported to the MATCH list, which effectively locks you out of high-risk processing under that entity for five years.

The mechanism, stated plainly: your copy is the compliance surface. Not your disclaimer. Not your age gate. The actual sentences a customer reads before they type in a card number.

What a Fixed Architecture Actually Looks Like

The fix isn't "add more disclaimers." Disclaimers stacked on top of dosing language don't neutralize the dosing language — they just create a page that contradicts itself, which is arguably worse in a manual review because it reads as intentional. The fix is enforcing research-only framing as a structural rule at the template level, not a legal afterthought bolted onto finished pages.

Concretely: every PDP gets rebuilt around a data-first structure — COA lot number and third-party lab results front and center, molecular specifications, storage and stability data, citations to the actual peer-reviewed research the compound appears in — instead of a "how to use" section. Where a competitor's PDP says "many users start at 250mcg," yours says "referenced in [Study X] at concentrations of 250mcg in vitro" and links the source. Same information density, entirely different legal posture, and — this matters for conversion — often more credible to the actual research-buyer persona than a testimonial is.

Testimonials get restructured too, not deleted. "Customer results" becomes "research community feedback," reframed around product handling, shipping speed, COA accuracy, and reconstitution stability — not physiological outcomes. It's a copy discipline, and it has to be enforced the same way brand voice is enforced: with an actual style guide that every writer, agency, and ad-buyer touching the site is required to follow, and a review step before anything goes live, including blog posts and paid landing pages, which are usually the first place the discipline breaks down because they're built fast and reviewed never.

This is exactly the kind of build we scope when we take on a peptide website design project — the underwriting agreement gets treated as a design constraint from day one, not a document that lives in a Google Drive folder nobody references after launch. Product templates are built so a non-compliant sentence physically doesn't fit the layout — there's no field for "recommended dose," only fields for lab data, citations, and handling specs. That's the only version of "compliance" that survives six months of a growth team iterating on conversion rate without a lawyer in the room.

The Question Worth Asking Before Your Next Ad Campaign Launches

If your processor pulled your live site right now — not your application, not your disclaimer, the actual PDP a customer reads before checkout — would the copy match the MCC code you were boarded under? Most peptide founders have never asked that question, because the person who wrote the copy and the person who signed the merchant agreement have never been in the same conversation. That gap is exactly where a rolling reserve or a MATCH listing comes from, and it doesn't show up until the account is already in remediation. If you're not sure what your own product pages would look like under that review, that's worth a conversation before your next campaign spends another dollar against an account that's one chargeback spike from getting shut off.